title: Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
abstract: The effects of the novel compound, (-)-OSU6162 ((S)-(-)-3-methylsulfonylphenyl-1-propylpiperidine), on rotational behavior induced by dopamine receptor agonists was investigated in common marmosets (Callithrix jacchus) with unilateral 6-hydroxydopamine lesions. (-)-OSU6162 per se displayed no effect on the animals' behavior. On the other hand, pretreatment with (-)-OSU6162 attenuated rotational behavior induced by apomorphine (apomorphini hydrochloridum), L-DOPA (3,4-dihydroxyphenylalanine), and the dopamine D2 receptor agonist, quinpirole (trans-(-)-4aR-4,4a, 5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolol[3,4-g]quinoline hydrochloride), without inducing motor impairment such as akinesia or dystonia. In addition, treatment with (-)-OSU6162 for 5 consecutive days almost completely abolished the rotational behavior provoked by apomorphine and produced a transient subsensitization of such apomorphine-induced effects after it was discontinued. Moreover, pretreatment with (-)-OSU6162 in two monkeys augmented the rotational behavior elicited by the dopamine D1 receptor agonists, SKF-81297 (R(+)-6-chloro-7,8,dihydroxy-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine hydrobromide) and A-77636 ((-)-(1R, 3S)-3-adamantyl-1-(aminomethyl)-3,4-dihydro-5, 6-dihydroxy-1H-2-benzopyran hydrochloride). The findings indicate that (-)-OSU6162 can exert indirect state-dependent effects that differentially affect dopamine D1 and dopamine D2 receptor agonist-induced behavior.
authors.affiliation: Department of Neuroscience, Neurology, University Hospital, Uppsala, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Ekesbo
authors.forename: P E
authors.initials: PE
authors.lastname: Andrén
authors.forename: L M
authors.initials: LM
authors.lastname: Gunne
authors.forename: C
authors.initials: C
authors.lastname: Sonesson
authors.forename: J
authors.initials: J
authors.lastname: Tedroff
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology; D002144:Callithrix; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D016627:Oxidopamine; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology*; D019257:Quinpirole / Q000494:pharmacology; D012399:Rotation
chemical_list: D001552:Benzazepines; D001578:Benzopyrans; D018492:Dopamine Antagonists; D010880:Piperidines; C109513:OSU 6162; C079415:A 77636; D019257:Quinpirole; D007980:Levodopa; C067113:SK&F 81297; D016627:Oxidopamine; D001058:Apomorphine; D000218:Adamantane